An anonymous director reports

VVT MED ANNOUNCES DEBT SETTLEMENT AND EQUITY INCENTIVE GRANTS TO STRENGTHEN CAPITAL STRUCTURE

VVT Med Inc. has proposed debt settlement transactions, together with grants of stock options and restricted share units to directors and employees.

Debt settlement to strengthen capital structure

VVT Med announces that it intends to enter into agreements with various vendors to settle a total of $212,939.76 of outstanding indebtedness through the issuance of 586,096 common shares, of which 125,000 at a deemed price of 56 cents per share and 461,096 at a deemed price of 31 cents per share.

The issuance of shares pursuant to the proposed debt settlement arrangement is subject to approval by the TSX Venture Exchange. The shares will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws and TSX Venture Exchange policies. Completion of the proposed debt settlement remains conditional upon the execution of definitive agreements and receipt of final approval from the TSX-V.

Equity incentive grants

The company announces that it has granted 688,773 stock options to the company's advisory board and to employees pursuant to the terms of the company's stock option plan. Of this amount, 240,000 participant options were granted to the advisory board directors and the remaining 448,773 participant options were granted to employees. The participant options shall vest at a rate of 8.33 per cent every quarter over a period of three years. All Participant Options shall have an exercise price of 56 cents and shall expire five years after their grant.

In addition, the company granted 912,519 restricted share units to directors and employees pursuant to the terms of the company's RSU plan. Of this amount, 792,519 participant RSUs were granted to directors. The remaining 120,000 participant RSUs were granted to employees.

Additional corporate information

For completeness, the company notes that the management cease trade order previously issued in connection with the company's financial reporting requirements was revoked on July 2, 2026, following the filing of the required records. The revocation order was issued by the British Columbia Securities Commission. The company is not currently subject to the management cease trade order.

About VVT Med Inc.

VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few Food and Drug Administration-cleared, stand-alone companies offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.